Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Trial Details
- NCT ID
- NCT06590857
- Phase
- PHASE1 / PHASE2
- Sponsor
- RayzeBio, Inc.
- Status
- RECRUITING
- Cancer Type
- Breast Cancer
- Interventions
- RYZ101
- Standard of Care Endocrine Therapy
- Locations (sample)
- Phoenix, Arizona, United States|33.44838,-112.07404
- Irvine, California, United States|33.66946,-117.82311
- San Diego, California, United States|32.71571,-117.16472
- Santa Monica, California, United States|34.01949,-118.49138
- Longmont, Colorado, United States|40.16721,-105.10193
Key Eligibility Criteria
- Subjects must meet all the following criteria for enrollment in the study:
- Histologically confirmed, ER+, HER2-negative, locally advanced and unresectable or metastatic breast cancer not amenable to treatment with curative…
- Adequate renal, hematologic, and hepatic function
- Additional inclusion criteria for Monotherapy arm:
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →